The cost-effectiveness of biomarkers for predicting the development of oesophageal adenocarcinoma

Alimentary Pharmacology and Therapeutics

Volumn 22, Issue 2, 2005, Pages 135-146

  Rubenstein, J H ^a   Vakil, N ^b   Inadomi, J M ^a,c  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c Center for Practice Management and Outcomes Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CANCER RISK; CLINICAL ARTICLE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIAGNOSTIC ACCURACY; DYSPLASIA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS RESECTION; GASTROESOPHAGEAL REFLUX; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; MALE; PRIORITY JOURNAL; PROBABILITY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ADENOCARCINOMA; BIOLOGICAL MARKERS; COST-BENEFIT ANALYSIS; ESOPHAGEAL NEOPLASMS; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; SENSITIVITY AND SPECIFICITY;

EID: 22844431753     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02536.x     Document Type: Article

References (68)

1. Shaheen N, Ransohoff DF. Gastro-oesophageal reflux, barrett oesophagus, and oesophageal cancer: scientific review. JAMA 2002; 287: 1972-81.
2. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr. Rising incidence of adenocarcinoma of the oesophagus and gastric cardia. JAMA 1991; 265: 1287-9.
3. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of oesophageal and gastric carcinoma in the United States. Cancer 1998; 83: 2049-53.
4. Peters JH, Clark GW, Ireland AP, Chandrasoma P, Smyrk TC, DeMeester TR. Outcome of adenocarcinoma arising in Barrett's oesophagus in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg 1994; 108: 813-21.
5. Streitz JM Jr , Andrews CW Jr, Ellis FH Jr. Endoscopic surveillance of Barrett's oesophagus. Does it help? J Thorac Cardiovasc Surg 1993; 105: 383-7.
6. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastro-oesophageal reflux as a risk factor for oesophageal adenocarcinoma. N Engl J Med 1999; 340: 825-31.
7. Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's oesophagus. Amer J Gastroenterol 2002; 97: 1888-1895.
8. Spechler SJ, Robbins AH, Rubins HB, et al. Adenocarcinoma and Barrett's oesophagus. An overrated risk? Gastroenterology 1984; 87: 927-33.
9. Provenzale D, Schmitt C, Wong JB. Barrett's oesophagus: a new look at the surveillance based on emerging estimates of cancer risk. Amer J Gastroenterol 1999; 94: 2043-53.
10. Sonnenberg A, Soni A, Sampliner RE. Medical decision analysis of endoscopic surveillance of Barrett's ooesophagus to prevent ooesophageal adenocarcinoma. Aliment Pharmacol Ther 2002; 16: 41-50.
11. Inadomi JM, Sampliner R, Lagergren J, Lieberman D, Fendrick M, Vakil N. Screening and surveillance for Barrett Oesophagus in high-risk groups: a cost-utility analysis. Ann Intern Med 2003; 138: 176-86.
12. Shaheen N, Crosby M, Bozymski E, Sandler R. Is there publication bias in the reporting of cancer risk in Barrett's oesophagus? Gastroenterology 2000; 119: 333-8.
13. Ormsby AH, Petras RE, Henricks WH, et al. Observer variation in the diagnosis of superficial ooesophageal adenocarcinoma. Gut 2002; 51: 671-6.
14. Skacel M, Petras RE, Gramlich TL, Sigel JE, Richter JE, Goldblum JR. The diagnosis of low-grade dysplasia in Barrett's oesophagus and its implications for disease progression. Amer J Gastroenterol 2000; 95: 3383-7.
15. Alikhan M, Rex D, Khan A, Rahmani E, Cummings O, Ulbright TM. Variable pathologic interpretation of columnar lined oesophagus by general pathologists in community practice. Gastrointest Endosc 1999; 50: 23-6.
16. Bani-Hani K, Martin IG, Hardie LJ, et al. Prospective study of cyclin D1 overexpression in Barrett's oesophagus: association with increased risk of adenocarcinoma. J Natl Cancer Inst 2000; 92: 1316-21.
17. Weston AP, Banerjee SK, Sharma P, Tran TM, Richards R, Cherian R. p53 protein overexpression in low grade dysplasia (LGD) in Barrett's oesophagus: immunohistochemical marker predictive of progression. Amer J Gastroenterol 2001; 96: 1355-62.
18. Reid BJ, Blount PL, Rabinovitch PS. Biomarkers in Barrett's oesophagus. Gastrointest Endosc Clin N Am 2003; 13: 369-97.
19. Wild CP, Forman D. Surveillance for Barrett's ooesophagus. It is too early to dismiss surveillance programmes. BMJ 2001; 322: 1125.
20. Reid BJ, Levine DS, Longton G, Blount PL, Rabinovitch PS. Predictors of progression to cancer in Barrett's oesophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Amer J Gastroenterol 2000; 95: 1669-76.
21. Rabinovitch PS, Longton G, Blount PL, Levine DS, Reid BJ. Predictors of progression in Barrett's oesophagus III: baseline flow cytometric variables. Amer J Gastroenterol 2001; 96: 3071-83.
22. Caygill CP, Reed PI, Johnston BJ, Hill MJ, Ali MH, Levi S. A single centre's 20 years' experience of columnar-lined (Barrett's) ooesophagus diagnosis. Eur J Gastroenterol Hepatol 1999; 11: 1355-8.
23. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's oesophagus: a prospective study of 170 patients followed 4.8 years. Amer J Gastroenterol 1997; 92: 212-5.
24. Provenzale D, Kemp A, Arora S, Wong JB. A Guide for surveillance of patients with Barrett's oesophagus. Amer J Gastroenterol 1994; 89: 670-80.
25. Rubenstein J, Inadomi J. Is the diagnosis of Barrett's worse than the disease? Gastroenterology 2004; 126: A-602.
26. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
27. 7 Galipeau PC, Li X, Longton G, et al. A panel of molecular and cytometric markers in Barrett's Oesophagus predicts progression to oesophageal adenocarcinoma [Abstract]. Gastroenterology 2004; 126: A-114.
28. Corley DA, Levin TR, Habel LA, Weiss NS, Buffler PA. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology 2002; 122: 633-40.
29. van Sandick JW, van Lanschot JJ, Kuiken BW, Tytgat GN, Offerhaus GJ, Obertop H. Impact of endoscopic biopsy surveillance of Barrett's ooesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut 1998; 43: 216-22.
30. Sharma P, McQuaid K, Dent J, et al. A critical review of the diagnosis and management of Barrett's oesophagus: the AGA Chicago Workshop. Gastroenterology 2004; 127: 310-30.
31. Hirota WK, Loughney TM, Lazas DJ, Maydonovitch CL, Rholl V, Wong RK. Specialized intestinal metaplasia, dysplasia, and cancer of the oesophagus and esophagogastric junction: prevalence and clinical data. Gastroenterology 1999; 116: 277-85.
32. Bonelli L. Barrett's oesophagus: results of a multicentric survey G.O.S.P.E. (Gruppo Operative per lo Studio delle Precancerosi Esofagee). Endoscopy 1993; 25: 652-4.
33. Winters C Jr, Spurling TJ, Chobanian SJ , et al. Barrett's oesophagus. A prevalent, occult complication of gastro-oesophageal reflux disease. Gastroenterology 1987; 92: 118-24.
34. Weston AP, Krmpotich P, Makdisi WF, et al. Short segment Barrett's oesophagus: clinical and histological features, associated endoscopic findings, and association with gastric intestinal metaplasia. Ame J Gastroenterol 1996; 91: 981-6.
35. Caygill CP, Reed PI, Hill MJ, Watson A. An initial comparison of nine centres registering patients with the UK National Barrett's Ooesophagus Registry (UKBOR). Eur J Cancer Prev 1999; 8: 539-42.
36. Johnston MH, Hammond AS, Laskin W, Jones DM. The prevalence and clinical characteristics of short segments of specialized intestinal metaplasia in the distal oesophagus on routine endoscopy. Amer J Gastroenterol 1996; 91: 1507-11.
37. Hameeteman W, Tytgat GN, Houthoff HJ, van den Tweel JG. Barrett's oesophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989; 96: 1249-56.
38. O'Connor JB, Falk GW, Richter JE. The incidence of adenocarcinoma and dysplasia in Barrett's oesophagus: report on the Cleveland Clinic Barrett's Oesophagus Registry. Amer J Gastroenterol 1999; 94: 2037-42.
39. Sharma P, Morales TG, Bhattacharyya A, Garewal HS, Sampliner RE. Dysplasia in short-segment Barrett's oesophagus: a prospective 3-year follow-up. Amer J Gastroenterol 1997; 92: 2012-6.
40. Schnell TG, Sontag SJ, Chejfec G, et al. Long-term nonsurgical management of Barrett's oesophagus with high-grade dysplasia. Gastroenterology 2001; 120: 1607-19.
41. Soni A, Sampliner RE, Sonnenberg A. Screening for high-grade dysplasia in gastro-oesophageal reflux disease: is it cost-effective? Amer J Gastroenterol 2000; 95: 2086-93.
42. Weston AP, Badr AS, Hassanein RS. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma. Amer J Gastroenterol 1999; 94: 3413-9.
43. Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar-lined (Barrett's) oesophagus. N Engl J Med 1985; 313: 857-9.
44. Williamson WA, Ellis FH Jr, Gibb SP, et al. Barrett's oesophagus. Prevalence and incidence of adenocarcinoma. Arch Intern Med 1991; 151: 2212-6.
45. Sharma P, Reker D, Falk G, Johnston M, Weston A, Sampliner R. Progression of Barrett's oesophagus to high grade dysplasia and cancer: preliminary results of the BEST (Barrett's Oesophagus Study) trial [Abstract]. Gastroenterology 2001; 120: 16.
46. Dent J, Bremner CG, Collen MJ, Haggitt RC, Spechler SJ. Barrett's ooesophagus. J Gastroenterol Hepatol 1991; 6: 1-22.
47. Katz D, Rothstein R, Schned A, Dunn J, Seaver K, Antonioli D. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's oesophagus. Amer J Gastroenterol 1998; 93: 536-41.
48. Schoenfeld P, Johnston M, Piorkowski M, Jones DM, Eloubeidi M, Provenzale D. Effectiveness and patient satisfaction with nurse-directed treatment of Barrett's oesophagus. Amer J Gastroenterol 1998; 93: 906-10.
49. Weston AP, Sharma P, Topalovski M, Richards R, Cherian R, Dixon A. Long-term follow-up of Barrett's high-grade dysplasia. Amer J Gastroenterol 2000; 95: 1888-93.
50. Robertson CS, Mayberry JF, Nicholson DA, James PD, Atkinson M. Value of endoscopic surveillance in the detection of neoplastic change in Barrett's ooesophagus. Br J Surg 1988; 75: 760-3.
51. Van der Veen AH, Dees J, Blankensteijn JD, Van Blankenstein M. Adenocarcinoma in Barrett's ooesophagus: an overrated risk. Gut 1989; 30: 14-8.
52. Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastro-oesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 2001; 285: 2331-8.
53. Weston AP, Badr AS, Hassanein RS. Prospective multivariate analysis of factors predictive of complete regression of Barrett's oesophagus. Amer J Gastroenterol 1999; 94: 3420-6.
54. Menke-Pluymers MB, Schoute NW, Mulder AH, Hop WC, van Blankenstein M, Tilanus HW. Outcome of surgical treatment of adenocarcinoma in Barrett's ooesophagus. Gut 1992; 33: 1454-8.
55. Ellis FH Jr, Heatley GJ, Krasna MJ, Williamson WA, Balogh K. Esophagogastrectomy for carcinoma of the oesophagus and cardia: a comparison of findings and results after standard resection in three consecutive eight-year intervals with improved staging criteria. J Thorac Cardiovasc Surg 1997; 113: 836-46; discussion 846-8.
56. Skinner DB. En bloc resection for neoplasms of the oesophagus and cardia. J Thorac Cardiovasc Surg 1983; 85: 59-71.
57. Ellis FH Jr, Gibb SP, Watkins E Jr. Esophagogastrectomy. A safe, widely applicable, and expeditious form of palliation for patients with carcinoma of the oesophagus and cardia. Ann Surg 1983; 198: 531-40.
58. Nguyen NT, Schauer P, Luketich JD. Minimally invasive oesophagectomy for Barrett's oesophagus with high-grade dysplasia. Surgery 2000; 127: 284-90.
59. Wolfe WG, Vaughn AL, Seigler HF, Hathorn JW, Leopold KA, Duhaylongsod FG. Survival of patients with carcinoma of the oesophagus treated with combined-modality therapy. J Thorac Cardiovasc Surg 1993; 105: 749-55; discussion 755-6.
60. Galandiuk S, Hermann RE, Cosgrove DM, Gassman JJ. Cancer of the oesophagus. The Cleveland clinic experience. Ann Surg 1986; 203: 101-8.
61. DeMeester TR, Zaninotto G, Johansson KE. Selective therapeutic approach to cancer of the lower oesophagus and cardia. J Thorac Cardiovasc Surg 1988; 95: 42-54.
62. Wu YK, Huang KC. Chinese experience in the surgical treatment of carcinoma of the oesophagus. Ann Surg 1979; 190: 361-5.
63. Earlam R, Cunha-Melo JR. Ooesophageal squamous cell carcinoma: I. A critical review of surgery. Br J Surg 1980; 67: 381-90.
64. Pera M, Trastek VF, Carpenter HA, Allen MS, Deschamps C, Pairolero PC. Barrett's oesophagus with high-grade dysplasia: an indication for oesophagectomy? Ann Thorac Surg 1992; 54: 199-204.
65. National Center for Health Statistics. Vital Statistics of the United States 2000. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics, Division of Data Services, 2001.
66. Silvis SE, Nebel O, Rogers G, Sugawa C, Mandelstam P. Endoscopic complications: results of the 1974 American Society for Gastrointestinal Endoscopy survey. J Amer Med Assoc 1976; 235: 928-30.
67. Habr-Gama A, Waye JD. Complications and hazards of gastrointestinal endoscopy. World J Surg 1989; 13: 193-201.
68. Gorelick AB, Inadomi JM, Barnett JL. Unsedated small-caliber oesophagogastroduodenoscopy (EGD): less expensive and less time-consuming than conventional EGD. J Clin Gastroenterol 2001; 33: 210-4.